Actively Recruiting
Study of Adherence, Persistence, and Effectiveness of Alirocumab 300 mg Treatment for Hypercholesterolaemia in Italy
Led by Federico II University · Updated on 2026-01-29
1500
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating how well patients with hypercholesterolaemia in Italy stick to and respond to treatment with alirocumab 300 mg. This observational study focuses on patients receiving this medication in real-life settings to better understand adherence, persistence, and treatment effectiveness over time. Participants in this study are patients already taking alirocumab 300 mg injections. The study observes their treatment without assigning interventions, tracking outcomes over periods of 6, 12, 24, and 36 months to assess adherence, persistence, and efficacy of the medication. During the study, researchers will collect data at regular intervals up to 36 months to evaluate treatment adherence, persistence, efficacy, and safety. Participants ongoing treatment will be monitored through clinical assessments and records, with no additional treatment required as part of the study. The total participation time can last up to three years.
CONDITIONS
Brief Title
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy
Research Team
P
Pasquale Perrone Filardi
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
